Celerus Diagnostics, developer of the Wave RPD System and global leader in rapid immunohistochemistry ("IHC") for cancer diagnosis, announced today that the Company has been issued three important patents by the United States Patent and Trademark Office. Issuance of the patents, covering key technologies that enable proprietary Rapid IHC®, puts the company on pace in its pursuit of global patent coverage for its revolutionary technologies.
"Receiving the patents and protecting our core technology is a significant and timely milestone for the company due to the pending global release of its fully automated product line," said Chief Executive Officer Rusty Reed. "Our ability to perform fully automated, rapid IHC is completely unmatched in the cancer diagnostics industry.
The Celerus Wave System is a valuable tool to expedite patient care and help doctors to make treatment option decisions sooner. The system also benefits hospitals by accelerating diagnostic throughput and enhancing laboratory efficiencies.
"Rapid IHC (on the Wave System) is cutting-edge technology that will change the field of immunohistochemistry. It will change the expectation for how and when results are received," said Chief Product Officer Jason Lusk.
Study unravels the link between colorectal cancer risk and steatotic liver disease